While surgery has long been the standard for removing solid tumors, a revolutionary technique called histotripsy is offering an alternative, as reported on MedPage Today. Histotripsy uses high-intensity, focused ultrasound waves to create “bubble clouds” within the cancer cells. These microscopic bubbles expand and collapse so rapidly that they mechanically rupture the tumor, effectively liquefying it without heat or radiation. They can be highly accurate in focusing only on the cancerous tumor itself.
Some recent studies have highlighted these advantages:
- Precision and Safety: Histotripsy targets the tumor with sub-millimeter accuracy, sparing critical structures like blood vessels and bile ducts that are often at risk during a scalpel-based surgery.
- Immune System Activation: Early data suggests that as the body cleans up the “cellular debris” left behind by the ultrasound, it may trigger an abscopal effect—essentially training the immune system to recognize and attack cancer cells elsewhere in the body.
- Rapid Recovery: Because there are no incisions, most patients undergo the procedure as outpatients and return to normal activity within days, rather than the weeks required for surgical recovery.
“I tell patients this is ‘Star Wars’ technology because there are no cuts, there’s no poking… It’s all happening with a focused beam of ultrasound.” — Dr. Jennifer Linehan, Saint John’s Health Center.
“Histotripsy is a promising technology that may allow us to treat tumors we’d otherwise have no good options for. It is not a miracle cure, but it can be a very useful tool.” — MD Anderson Cancer Center Insights.
While the technical success of destroying individual tumors is well-documented, the medical community remains cautious about replacing surgery entirely. Large-scale oncology data comparing the long-term survival rates of ultrasound-treated patients versus those who underwent traditional surgery is still roughly two years away (expected in 2028). Doctors need this longitudinal evidence to confirm that “blasting” the cancer away is just as effective at preventing recurrence as physically cutting it out.
According to an article in MEDPAGE Today- reporting on a meeting of the European Association of Urology, that discussed the first randomized trial comparing treating prostate cancer surgery with either robotic surgery or ultrasound ablation of the tumor called the CAPTAIN study, the results are promising.
Patients were randomized to TULSA- a form of ultrasound ablation, or local standard-of-care prostatectomy. The safety endpoints were pad-free continence and erectile function at 1 year. The trial has a composite efficacy endpoint of freedom from treatment failure at 3 years. Treatment failure comprises delivery of any additional intervention for prostate cancer, development of metastatic disease, or prostate cancer-specific death
Perioperative outcomes favored TULSA, including postprocedure blood loss (0 vs 150 mL, P<0.0001) and length of stay (0.3 vs 1.1 days, P<0.0001). Patients in the TULSA arm had less pain during the first week after treatment. Patient-reported overall health at 30 days also favored TULSA (P<0.05). Mean time to recovery was 10 days with TULSA and 19 days with prostatectomy (P<0.05). Klotz reported that 6.3% of prostatectomy patients required hospitalization versus 0.7% of the TULSA group (P<0.05), and 1.6% of the prostatectomy group required intensive care unit admission versus none of the TULSA patients.
At 6 months, half of the patients in the TULSA arm met the composite primary endpoint versus 24% of the prostatectomy group (risk ratio 2.1, P<0.05).
Similarly UCHealth, recently reported the use of histotripsy to ablate inoperable tumors in the liver. They report a 95% success rate and a very low complication rate.
These are early results, but very promising.
